Application of arsenicals in the treatment of relapsed and refractory multiple myeloma
10.3760/cma.j.issn.1009-9921.2017.12.007
- VernacularTitle:砷剂在复发难治多发性骨髓瘤中的应用
- Author:
Jing SUN
1
;
Lei CHEN
;
Hongxia MA
;
Xiujuan DONG
Author Information
1. 450000,郑州市第三人民医院血液科
- Keywords:
Multiple myeloma;
Recurrence;
Refractory;
Arsenites
- From:
Journal of Leukemia & Lymphoma
2017;26(12):730-733
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and adverse reactions of arsenicals in the treatment of refractory or relapsed multiple myeloma. Methods The data of 21 patients with refractory or relapsed multiple myeloma were retrospectively analyzed, including 10 patients with arsenicals (the arsenious acid group) and 11 cases treated with new regimens or treatments containing Bortezomib (the control group). The arsenious acid group comprised 5 males and 5 females, with the average age of (62±5) years old. The control group comprised 7 males and 4 females, with the average age of (59±9) years old. The total effective rate and overall survival (OS) in both groups were observed after 2 treatment courses. Results The median effective time and the total effective cases in the arsenious acid group and the control group was 8.00 mouths (6.00-9.00 mouths) and 3.50 mouths (1.00-24.00 mouths), 3 (3/10) and 6 (6/11) respectively. There was a statistically significant difference in the total effective rate (P= 0.245). There was no significant difference in the adverse reactions rate between the two groups (P> 0.05). The median OS time was 10.00 months (8.00-24.00 months) and 6.00 months (1.00-69.00 months) in the arsenious acid group and the control group respectively (P=0.900). Conclusion The arsenious acid in the treatment of refractory or relapsed multiple myeloma can not increase the incidence of adverse reactions with a favorable cost performance.
